# Ligand Pharmaceuticals share price today (Ligand Pharmaceuticals Incorporated, LGND)

> Ligand Pharmaceuticals Incorporated's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. LGND · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/lgnd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $299.00 (+47.7% in a year)
- P/E: 125.0×, over 4.3 years
- Revenue (Jun 2026): $63.7 M (+33.7% on a year ago)
- Profit (Jun 2026): $48.5 M (+900.8% on a year ago)
- Operating margin: 13.5% (−6.9 points on a year ago)
- ROE: 12%, FY25
- ROIC: 3.0%, against a 8.3% cost of capital: −5.3 points
- Profit that came in as cash: 76%, last 3 years

Biggest thing to watch: the price has already been rising for 74 weeks, so timing is the risk more than the business. ## What is the Ligand Pharmaceuticals share price today? Ligand Pharmaceuticals Incorporated's share price was $299.00 at the close on 5 November 2026. It has been rising for 74 weeks. That is 17.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between $184 and $323, and at that close it sat 83% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 10 years the share price moved +138% while the S&P 500 moved +245%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Ligand Pharmaceuticals pay? Ligand Pharmaceuticals Incorporated pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Ligand Pharmaceuticals on? Ligand Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Ligand Pharmaceuticals profitable? Ligand Pharmaceuticals Incorporated earned $48.5 M of net profit in the Jun 2026 quarter, +900.8% on the same quarter a year earlier. Full-year FY25 profit was $124 M. Over 4 years profit has grown 21.5% a year on average. That is 76.2% of the quarter's revenue. The same quarter a year earlier earned $4.8 M. 6 of the last 12 reported quarters were loss-making. ## How much revenue does Ligand Pharmaceuticals make, and is it growing? Ligand Pharmaceuticals Incorporated reported $63.7 M of revenue in the Jun 2026 quarter, +33.7% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 4 years it has grown 2.6% a year on average. The last full year, FY25, came in at $268 M. The last four reported quarters add to $291 M. FY25 revenue was $268 M, +60.4% on the year before. Recent pace: the last four quarters grew +52.5% on average, against 2.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +54.9%, against +47.5% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Ligand Pharmaceuticals keep? Ligand Pharmaceuticals Incorporated's operating margin was 13.5% in the Jun 2026 quarter, 6.9 percentage points lower than the same quarter a year ago. Across 5 years it has been between 1.5% and 27.4%. The latest quarter is within that range. Why the margin moved: operating margin changed −6.9 percentage points on the year while gross margin changed −8.2 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Ligand Pharmaceuticals' profit turning into cash? Over the last 3 years, 76% of Ligand Pharmaceuticals Incorporated's reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in $49.4 M of operating cash against $124 M of profit. After $452 K of spending on assets, $48.9 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Ligand Pharmaceuticals' cash go? Ligand Pharmaceuticals Incorporated does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $5.8 M on assets over the last 3 years. Averaged over those years that is 0.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $5.8 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Ligand Pharmaceuticals' P/E ratio, and how does it compare with its own history? Ligand Pharmaceuticals Incorporated's P/E is 125.0×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 3 years the price moved +76.9% a year; about +123.1% a year came from earnings growth and about −46.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Ligand Pharmaceuticals business getting better or worse? Ligand Pharmaceuticals Incorporated's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Ligand Pharmaceuticals earn on its capital? Ligand Pharmaceuticals Incorporated earned a ROE of 12% in FY25. That is up from a low of −6% in FY22. Its return on capital used (ROIC) is 5.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 46.4% net margin and 0.17× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 46.4% net margin × 0.17× asset turnover × 1.53× leverage (assets divided by equity) ≈ 12.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 3.0% − 8.3% = −5.3 percentage points. The 8.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 3.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 5.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Ligand Pharmaceuticals have too much debt? Ligand Pharmaceuticals Incorporated has total debt of $1.1 B against shareholder equity of $968 M as of Jun 2026, so its debt is 1.17× its equity. Year by year, that ratio went from 0.40 in FY21 to 0.44 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Ligand Pharmaceuticals shareholding pattern? 12.8% of Ligand Pharmaceuticals Incorporated's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 9.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Ligand Pharmaceuticals from balance-sheet trouble? For Ligand Pharmaceuticals Incorporated, the Z-score is 2.72. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.72 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Ligand Pharmaceuticals rank in its industry? There is no score against its industry: Ligand Pharmaceuticals Incorporated is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Ligand Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Ligand Pharmaceuticals in size? Ligand Pharmaceuticals is the 40th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Axsome Therapeutics, Inc., Ionis Pharmaceuticals, Inc. and Mirum Pharmaceuticals, Inc. Just below it: CG Oncology, Inc., Scholar Rock Holding Corporation and PTC Therapeutics, Inc. ### Biotechnology companies close in size

1. [Axsome Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/axsm) $6.8 billion
2. [Ionis Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/ions) $6.4 billion
3. [Mirum Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mirm) $6.1 billion
4. Ligand Pharmaceuticals Incorporated $6 billion
5. [CG Oncology, Inc.](https://www.sectoralpha.in/us/stocks/cgon) $5.7 billion
6. [Scholar Rock Holding Corporation](https://www.sectoralpha.in/us/stocks/srrk) $5.5 billion
7. [PTC Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptct) $5.5 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Teleflex Incorporated](https://www.sectoralpha.in/us/stocks/tfx) $6.4 billion · Medical Instruments & Supplies
2. [Mirum Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mirm) $6.3 billion · Biotechnology
3. Ligand Pharmaceuticals Incorporated $6.3 billion
4. [Matson, Inc.](https://www.sectoralpha.in/us/stocks/matx) $6.3 billion · Marine Shipping
5. [RLI Corp.](https://www.sectoralpha.in/us/stocks/rli) $6.3 billion · Insurance - Property & Casualty

## What else do people ask about Ligand Pharmaceuticals? ### What is Ligand Pharmaceuticals's stock price today? Ligand Pharmaceuticals Incorporated's stock price is $299.00, +47.7% over the past year. The whole company is worth $6.0 B on the market. In the last 52 weeks it traded between $184 to $323; today it is 83% of the way up from the low, 17.3% above its 200-day average (as of 5 November 2026). ### What were Ligand Pharmaceuticals's latest quarterly results? Ligand Pharmaceuticals Incorporated reported revenue of $63.7 M and net profit of $48.5 M for the Jun 2026 quarter. Revenue rose 33.7% and profit rose 900.8% compared with a year earlier. Earnings per share were $2.22. The operating margin was 13.5%, 6.9 percentage points lower than a year earlier (as of 5 November 2026). ### What is Ligand Pharmaceuticals's market cap? Ligand Pharmaceuticals Incorporated's market capitalisation is $6.0 B at a stock price of $299.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Ligand Pharmaceuticals performing? Ligand Pharmaceuticals Incorporated's share price has been rising for 74 weeks. In its latest quarter, revenue rose 33.7% and profit rose 900.8% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running (as of 5 November 2026). ### Will Ligand Pharmaceuticals's stock price go up? This page does not forecast Ligand Pharmaceuticals Incorporated's stock price. What it shows instead: the stock price is $299.00, and it has been rising for 74 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Ligand Pharmaceuticals have too much debt? Yes, Ligand Pharmaceuticals Incorporated has a lot of debt: its debt is 1.20× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 5 November 2026). ### Where is Ligand Pharmaceuticals in its business cycle? Ligand Pharmaceuticals Incorporated's FY25 operating margin was 17.6%, against a 5-year range of 1.5% to 27.4%: the middle of its own range, neither a peak nor a low. The latest quarter was 13.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Ligand Pharmaceuticals story? Biggest thing to watch: the price has already been rising for 74 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Ligand Pharmaceuticals a stock worth studying right now? What the numbers show: Ligand Pharmaceuticals Incorporated's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.